A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

Gemici, Aliihsan; ÖZKALEMKAŞ, FAHİR; Dogu, Mehmet; Tekinalp, Atakan; ALACACIOĞLU, İNCİ; Guney, Tekin; Ince, Idris; GEDÜK, AYFER; ÇAĞLIYAN, GÜLSÜM; Maral, Senem; Serin, Istemi; GÜNDÜZ, EREN; Karakus, Volkan; Bekoz, Huseyin; Eren, Rafet; PINAR, İBRAHİM; Gunes, Ahmet; Sargin, Fatma; Sevindik, Omur

doi:10.1016/j.clml.2021.04.004

A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

Gemici A., ÖZKALEMKAŞ F., Dogu M. H., Tekinalp A., ALACACIOĞLU İ., Guney T., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.8, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 8
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.clml.2021.04.004
Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Anahtar Kelimeler: Bcl2, Inhibitor, Venetoclax, Acute myeloid leukemia, Real life, LOW-DOSE CYTARABINE, OLDER PATIENTS, BCL-2 INHIBITION, AZACITIDINE, SURVIVAL, CARE, AML
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.